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Table 1: Secondary Outcomes and Patient Characteristics
Figure 2: Provider Survey Results (n=118)
• There was an increase in the percentage of appropriate FQ 
prescriptions written.
• These results are consistent with prior AMS publications 
focusing on provider education and/or provider reporting.
Provider Support
• Tools to aid providers in selecting appropriate 
antimicrobial therapies and communicating effectively 
with patients about the risks and benefits of antimicrobial 
agents are imperative.
• While a specific medication class and population was 
focused on during this intervention, ongoing provider 
support is needed, such as:
• Education on outpatient AMS in a narrow-focused topic 
and patient population positively impacted prescribing.
• Ongoing support for AMS in the outpatient setting is 
needed and important.
Purpose
• To introduce an outpatient antimicrobial stewardship program.
• To determine the impact of provider education with feedback 
on prescribing habits related to FQ use in elderly patients.
Methodology
Preliminary Results
Health & Services
• Approximately 10% of adult outpatient visits result in an 
antibiotic prescription, making up approximately 60% of 
all antimicrobial prescribing.1
• The Society of Infectious Diseases Pharmacists and 
American Pharmacists Association state that pharmacists 
have a vital role in antibiotic stewardship in the 
outpatient setting.2
• The US Food and Drug Administration (FDA) and 
Infectious Diseases Society of America (IDSA) have 
published warnings for the following related to 
fluoroquinolone (FQ) use: 3,4
• Two-fold increased risk of aortic dissection
• Hypoglycemia risk that could lead to coma
• Mental health side effects, including agitation and 
delirium that can be seen with one dose
• Tendonitis and tendon rupture
• Clostridium difficile (OR = 3.9) with FQ exposure
• Institutional Review Board (IRB)-approved 
• Pre- and post- intervention study 
• Study Population
• Patients ≥65 years old who received a prescription for 
an oral FQ at an Oregon or Southwest Washington 
Providence Medical Group (PMG) clinic
• Exclusion criteria
• Prescription from a PMG medical resident-staffed 
clinic or hospital-based clinic
• FQ administered via topical, intravenous, otic, or 
ophthalmic route 
• FQ continued from a different encounter
• Patient is enrolled in hospice, palliative care, is a 
prisoner, or is pregnant
Pre-intervention
• Data collected for 
March 2018 and 
March 2019
• Individualized 
provider reports 
developed
• 15% of patients 
from each study 
month reviewed for 
secondary outcomes
Intervention
• Clinic pharmacists 
provided education 
on FQ risks and 
appropriate uses
• Individualized 
provider reports for 
March 2018 and 
2019 given to 
providers
• Provider pre- and 
post-education 
surveys conducted
Post-intervention
• Data collected for 
March 2020
• Individualized 
provider reports for 
March 2020 emailed 
to providers
• 15% of patients 
from final study 
month reviewed for 
secondary outcomes
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March 2018 
(n=41)
March 2019 
(n=32)
March 2020 
(n=18)
Average Age (years) 79 (65 – 102) 76 (65 – 96) 77 (66 – 92)
% male 27% 16% 27.8%
Average CrCl (mg/dL) 82.9 (13 – 138) 55.6 (12 – 102) 67 (26 – 106)
Encounter type
Telephone
Office visit
MyChart
Other
14 (34.1%)
22 (53.7%)
2 (4.9%)
3 (7.3%)
13 (40.6%)
18 (56.3%)
1 (3.1%)
0
9 (50%)
6 (33.3%)
1 (5.6%)
2 (11.1%)
Medication prescribed
Ciprofloxacin
Levofloxacin
Moxifloxacin
34 (82.9%)
6 (14.6%)
1 (2.5%)
26 (81.3%)
5 (15.6%)
1 (3.1%)
13 (72.2%)
5 (27.8%)
0
Indication
Cystitis
Pyelonephritis
Diverticulitis
Pneumonia
Other indication with guideline-directed antibiotic use
Other indication without guideline-directed antibiotic use
32 (78%)
0
2 (4.9%)
2 (4.9%)
2 (4.9%)
3 (7.3%)
15 (46.8%)
1 (3.1%)
5 (15.6%)
2 (6.3%)
7 (21.9%)
2 (6.3%)
9 (50%)
1 (5.6%)
2 (11.1%)
3 (16.6%)
2 (11.1%)
1 (5.6%)
% FQ therapy appropriate 1 (2.4%) 2 (6.3%) 5 (27.8%)
% FQ therapy inappropriate
Other guideline-directed therapy would be appropriate
FQ appropriate but wrong dose and/or duration
40 (97.6%)
29 (72.5%)
11 (27.5%)
30 (93.7%)
22 (73.3%)
8 (26.7%)
13 (72.2%)
9 (69.2%)
4 (30.8%)
Provider Comfort Level Discussing Risks and Benefits of FQ Therapy with Patients
23%
56%
15%
4% 2%
Very Comfortable
Somewhat Comfortable
Neutral
Somewhat Uncomfortable
Very Uncomfortable
Pre-Survey Post-Survey
65%
25%
6%
2% 2%
Figure 1: Primary Outcome (n=606)
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Provider-Identified Barriers to Antimicrobial Stewardship in the Outpatient Setting
Patient expectations for antimicrobial prescription (49%)
Time constraints when 
prescribing antibiotics 
(13%)
Concern for 
decreased 
patient 
satisfaction 
(17%)
Lack of 
standardized 
practice 
guidelines 
(13%)
EHR limitations (8%)
Primary Outcome
Secondary Outcomes
• Change in number of FQ prescriptions written for patients 
> 65 years of age in the primary care setting between 
March 2018 and 2019, and March 2019 and 2020.
Percentage of Providers Identifying 5 of 5 Risks Associated with FQ Therapy
84.10%
6.80%
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Study Limitations
• Unable to control for providers who were new to, or left, 
PMG during study years.
• Large viral pandemic during post-intervention study period 
likely altered prescribing practices.
• Small number of patients were reviewed for 
appropriateness of FQ prescriptions.
• Available reporting tools require manual chart review to 
accurately report FQ prescriptions per provider and 
appropriateness of each prescription.
• Education on appropriate antibiotic indications, 
doses and durations.
• Communication techniques for providers to discuss 
risks, benefits, and appropriateness of antimicrobial 
therapy with patients
• Techniques to aid in antimicrobial stewardship, such 
as delayed prescribing
• Enhanced reporting tools to offer provider-specific 
feedback on antimicrobial prescribing habits at a 
regular frequency, such as seasonally or quarterly 
• Percentage of appropriate FQ prescriptions written in each 
study period, determined by disease-specific guidelines. 
15% of FQ prescriptions from each study period identified 
from the primary outcome were included.
• Percentage of providers identifying 5 out of 5 risks 
associated with FQ therapy before and after education.
• Provider comfort level discussing risks and benefits of FQ 
therapy with patients before and after education.
• Provider-identified barriers to antimicrobial stewardship in 
the outpatient setting.
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Future Directions
• Finalize data collection and perform statistical analysis.
• Present study findings to clinical pharmacy department, 
pharmacy resident community, and PMG AMS workgroup.
• Develop system-level outpatient AMS program similar to 
existing inpatient AMS program.
• There was a reduction in FQ prescriptions written for patients 
> 65 years of age each March during the study period.
